{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:53:30Z","timestamp":1786985610207,"version":"build-2736575974"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.canlet.2021.06.022","type":"journal-article","created":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T04:40:29Z","timestamp":1625028029000},"page":"57-67","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["PPP2R4 dysfunction promotes KRAS-mutant lung adenocarcinoma development and mediates opposite responses to MEK and mTOR inhibition"],"prefix":"10.1016","volume":"520","author":[{"given":"Bob","family":"Meeusen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1067-9179","authenticated-orcid":false,"given":"Emanuela Elsa","family":"Cortesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judit","family":"Dom\u00e8nech Omella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Sablina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9252-843X","authenticated-orcid":false,"given":"Juan-Jose","family":"Ventura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6772-8448","authenticated-orcid":false,"given":"Veerle","family":"Janssens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2021.06.022_bib1","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"Ca - Cancer J. Clin."},{"key":"10.1016\/j.canlet.2021.06.022_bib2","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.lungcan.2018.07.013","article-title":"KRAS-Mutant non-small cell lung cancer: from biology to therapy","volume":"124","author":"Ferrer","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.canlet.2021.06.022_bib3","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.ccell.2020.03.013","article-title":"Targeting the MAPK pathway in KRAS-driven tumors","volume":"37","author":"Drosten","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2021.06.022_bib4","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1042\/bj3530417","article-title":"Protein phosphatase 2A: a highly regulated family of serine\/threonine phosphatases implicated in cell growth and signalling","volume":"353","author":"Janssens","year":"2001","journal-title":"Biochem. J."},{"key":"10.1016\/j.canlet.2021.06.022_bib5","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.bbamcr.2018.07.010","article-title":"Physiologic functions of PP2A: lessons from genetically modified mice","volume":"1866","author":"Reynhout","year":"2019","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"key":"10.1016\/j.canlet.2021.06.022_bib6","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.cell.2007.06.034","article-title":"PP2A: unveiling a reluctant tumor suppressor","volume":"130","author":"Mumby","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2021.06.022_bib7","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/j.1742-4658.2012.08579.x","article-title":"The biogenesis of active protein phosphatase 2A holoenzymes: a tightly regulated process creating phosphatase specificity","volume":"280","author":"Sents","year":"2013","journal-title":"FEBS J."},{"key":"10.1016\/j.canlet.2021.06.022_bib8","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1101\/gad.259903","article-title":"A novel and essential mechanism determining specificity and activity of protein phosphatase 2A (PP2A) in vivo","volume":"17","author":"Fellner","year":"2003","journal-title":"Genes Dev."},{"key":"10.1016\/j.canlet.2021.06.022_bib9","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.molcel.2006.07.008","article-title":"Crystal structure of the PP2A phosphatase activator: implications for its PP2A-specific PPIase activity","volume":"23","author":"Leulliot","year":"2006","journal-title":"Mol. Cell"},{"key":"10.1016\/j.canlet.2021.06.022_bib10","doi-asserted-by":"crossref","first-page":"e155","DOI":"10.1371\/journal.pbio.0050155","article-title":"Generation of active protein phosphatase 2A is coupled to holoenzyme assembly","volume":"5","author":"Hombauer","year":"2007","journal-title":"PLoS Biol."},{"key":"10.1016\/j.canlet.2021.06.022_bib11","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/cr.2013.138","article-title":"Structural basis of PP2A activation by PTPA, an ATP-dependent activation chaperone","volume":"24","author":"Guo","year":"2014","journal-title":"Cell Res."},{"key":"10.1016\/j.canlet.2021.06.022_bib12","first-page":"1","article-title":"Protein phosphatase 2A regulatory subunits and cancer","volume":"1795","author":"Eichhorn","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.canlet.2021.06.022_bib13","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.biocel.2017.10.002","article-title":"Tumor suppressive protein phosphatases in human cancer: emerging targets for therapeutic intervention and tumor stratification","volume":"96","author":"Meeusen","year":"2018","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.canlet.2021.06.022_bib14","doi-asserted-by":"crossref","first-page":"e229","DOI":"10.1016\/S1470-2045(12)70558-2","article-title":"Protein phosphatase 2A: a target for anticancer therapy","volume":"14","author":"Perrotti","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2021.06.022_bib15","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.biocel.2018.01.005","article-title":"Non-genomic mechanisms of protein phosphatase 2A (PP2A) regulation in cancer","volume":"96","author":"Kauko","year":"2018","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.canlet.2021.06.022_bib16","doi-asserted-by":"crossref","first-page":"6825","DOI":"10.1158\/0008-5472.CAN-16-2911","article-title":"PP2A Inactivation Mediated by PPP2R4 haploinsufficiency promotes cancer development","volume":"77","author":"Sents","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2021.06.022_bib17","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1038\/sj.onc.1203389","article-title":"Low frequency of alterations of the alpha (PPP2R1A) and beta (PPP2R1B) isoforms of the subunit A of the serine-threonine phosphatase 2A in human neoplasms","volume":"19","author":"Calin","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2021.06.022_bib18","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1245\/s10434-010-1313-8","article-title":"CIP2A is overexpressed in non-small cell lung cancer and correlates with poor prognosis","volume":"18","author":"Dong","year":"2011","journal-title":"Ann. Surg Oncol."},{"key":"10.1016\/j.canlet.2021.06.022_bib19","doi-asserted-by":"crossref","first-page":"14913","DOI":"10.18632\/oncotarget.3818","article-title":"Overexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer","volume":"6","author":"Liu","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2021.06.022_bib20","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.molmed.2008.02.001","article-title":"Multiple pathways regulated by the tumor suppressor PP2A in transformation","volume":"14","author":"Westermarck","year":"2008","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.canlet.2021.06.022_bib21","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S1535-6108(04)00026-1","article-title":"Identification of specific PP2A complexes involved in human cell transformation","volume":"5","author":"Chen","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2021.06.022_bib22","doi-asserted-by":"crossref","first-page":"10474","DOI":"10.1158\/0008-5472.CAN-10-2855","article-title":"Identification of PP2A complexes and pathways involved in cell transformation","volume":"70","author":"Sablina","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2021.06.022_bib23","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1289\/ehp.9193211","article-title":"Mechanisms of action of okadaic acid class tumor promoters on mouse skin","volume":"93","author":"Fujiki","year":"1991","journal-title":"Environ. Health Perspect."},{"key":"10.1016\/j.canlet.2021.06.022_bib24","doi-asserted-by":"crossref","first-page":"451","DOI":"10.4161\/cc.11.3.19057","article-title":"Mouse model for probing tumor suppressor activity of protein phosphatase 2A in diverse signaling pathways","volume":"11","author":"Walter","year":"2012","journal-title":"Cell Cycle"},{"key":"10.1016\/j.canlet.2021.06.022_bib25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0188910","article-title":"The tumor suppressor phosphatase PP2A-B56\u03b1 regulates stemness and promotes the initiation of malignancies in a novel murine model","volume":"12","author":"Janghorban","year":"2017","journal-title":"PloS One"},{"key":"10.1016\/j.canlet.2021.06.022_bib26","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/onc.2017.350","article-title":"Loss of protein phosphatase 2A regulatory subunit B56\u03b4 promotes spontaneous tumorigenesis in vivo","volume":"37","author":"Lambrecht","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2021.06.022_bib27","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1128\/MCB.05744-11","article-title":"Human cancer-associated mutations in the A\u03b1 subunit of protein phosphatase 2A increase lung cancer incidence in A\u03b1 knock-in and knockout mice","volume":"31","author":"Ruediger","year":"2011","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.canlet.2021.06.022_bib28","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/s41388-019-1012-2","article-title":"Inactivation of PP2A by a recurrent mutation drives resistance to MEK inhibitors","volume":"39","author":"O'Connor","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2021.06.022_bib29","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaq1093","article-title":"PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells","volume":"10","author":"Kauko","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.canlet.2021.06.022_bib30","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0021-9258(17)49933-9","article-title":"Protein phosphatase 2A activation as a therapeutic strategy for managing MYC-driven cancers","volume":"295","author":"Farrington","year":"2020","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2021.06.022_bib31","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1172\/JCI89548","article-title":"Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth","volume":"127","author":"Sangodkar","year":"2017","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.canlet.2021.06.022_bib32","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccell.2020.05.003","article-title":"Unbiased proteomic profiling uncovers a targetable GNAS\/PKA\/PP2A Axis in small cell lung cancer stem cells","volume":"38","author":"Coles","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2021.06.022_bib33","doi-asserted-by":"crossref","first-page":"4242","DOI":"10.1158\/0008-5472.CAN-19-0218","article-title":"The highly recurrent PP2A a\u03b1-subunit mutation P179R alters protein structure and impairs PP2A enzyme function to promote endometrial tumorigenesis","volume":"79","author":"Taylor","year":"2019","journal-title":"Can. Res."},{"key":"10.1016\/j.canlet.2021.06.022_bib34","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1172\/JCI68951","article-title":"PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells","volume":"123","author":"Neviani","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.canlet.2021.06.022_bib35","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.cell.2020.03.051","article-title":"Allosteric activators of protein phosphatase 2A display broad antitumor activity mediated by dephosphorylation of MYBL2","volume":"181","author":"Morita","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2021.06.022_bib36","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/ncb1110","article-title":"A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells","volume":"6","author":"Yeh","year":"2004","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.canlet.2021.06.022_bib37","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1128\/MCB.26.7.2832-2844.2006","article-title":"Protein phosphatase 2A regulatory subunit B56alpha associates with c-myc and negatively regulates c-myc accumulation","volume":"26","author":"Arnold","year":"2006","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.canlet.2021.06.022_bib38","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1038\/s41467-018-03327-4","article-title":"Eya3 partners with PP2A to induce c-Myc stabilization and tumor progression","volume":"9","author":"Zhang","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2021.06.022_bib39","doi-asserted-by":"crossref","first-page":"4406","DOI":"10.1046\/j.1432-1327.2000.01486.x","article-title":"Identification and characterization of alternative splice products encoded by the human phosphotyrosyl phosphatase activator gene","volume":"267","author":"Janssens","year":"2000","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.canlet.2021.06.022_bib40","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1101\/gad.943001","article-title":"Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras","volume":"15","author":"Jackson","year":"2001","journal-title":"Genes Dev."},{"key":"10.1016\/j.canlet.2021.06.022_bib41","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1038\/nprot.2009.95","article-title":"Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase","volume":"4","author":"DuPage","year":"2009","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.canlet.2021.06.022_bib42","doi-asserted-by":"crossref","first-page":"16878","DOI":"10.1038\/s41598-017-17204-5","article-title":"QuPath: open source software for digital pathology image analysis","volume":"7","author":"Bankhead","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.canlet.2021.06.022_bib43","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2021.06.022_bib44","doi-asserted-by":"crossref","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci. Signal."},{"key":"10.1016\/j.canlet.2021.06.022_bib45","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0046688","article-title":"Predicting the functional effect of amino acid substitutions and indels","volume":"7","author":"Choi","year":"2012","journal-title":"PloS One"},{"key":"10.1016\/j.canlet.2021.06.022_bib46","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1073\/pnas.0900121106","article-title":"Phosphorylation by Cdk2 is required for Myc to repress Ras-induced senescence in cotransformation","volume":"107","author":"Hydbring","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2021.06.022_bib47","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1101\/gad.836800","article-title":"Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability","volume":"14","author":"Sears","year":"2000","journal-title":"Genes Dev."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383521003074?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383521003074?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T15:58:38Z","timestamp":1759593518000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383521003074"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":47,"alternative-id":["S0304383521003074"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2021.06.022","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PPP2R4 dysfunction promotes KRAS-mutant lung adenocarcinoma development and mediates opposite responses to MEK and mTOR inhibition","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2021.06.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}